ACADIA PHARMACEUTICALS INC (ACAD) Stock Fundamental Analysis
NASDAQ:ACAD - Nasdaq - US0042251084 - Common Stock - Currency: USD
Taking everything into account, ACAD scores 6 out of 10 in our fundamental rating. ACAD was compared to 558 industry peers in the Biotechnology industry. ACAD is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ACAD is growing strongly while it is still valued neutral. This is a good combination! These ratings could make ACAD a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
In the past year ACAD was profitable.
In the past year ACAD had a positive cash flow from operations.
In the past 5 years ACAD reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: ACAD reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of ACAD (20.23%) is better than 97.51% of its industry peers.
The Return On Equity of ACAD (29.93%) is better than 97.69% of its industry peers.
The Return On Invested Capital of ACAD (9.30%) is better than 94.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.23% | ||
| ROE | 29.93% | ||
| ROIC | 9.3% |
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ACAD's Profit Margin of 22.99% is amongst the best of the industry. ACAD outperforms 95.73% of its industry peers.
ACAD has a Operating Margin of 8.84%. This is amongst the best in the industry. ACAD outperforms 93.77% of its industry peers.
ACAD has a Gross Margin of 92.08%. This is amongst the best in the industry. ACAD outperforms 93.24% of its industry peers.
In the last couple of years the Gross Margin of ACAD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.84% | ||
| PM (TTM) | 22.99% | ||
| GM | 92.08% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ACAD is destroying value.
ACAD has more shares outstanding than it did 1 year ago.
ACAD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ACAD has an Altman-Z score of 4.78. This indicates that ACAD is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ACAD (4.78) is better than 77.76% of its industry peers.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.78 |
ROIC/WACC0.96
WACC9.68%
2.3 Liquidity
A Current Ratio of 2.87 indicates that ACAD has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.87, ACAD is doing worse than 66.19% of the companies in the same industry.
ACAD has a Quick Ratio of 2.80. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.80, ACAD is doing worse than 64.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.87 | ||
| Quick Ratio | 2.8 |
3. Growth
3.1 Past
ACAD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 5000.00%, which is quite impressive.
ACAD shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.39%.
Measured over the past years, ACAD shows a very strong growth in Revenue. The Revenue has been growing by 23.08% on average per year.
EPS 1Y (TTM)5000%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
Revenue 1Y (TTM)22.39%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%18.7%
3.2 Future
ACAD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.65% yearly.
ACAD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.99% yearly.
EPS Next Y11.46%
EPS Next 2Y33.01%
EPS Next 3Y49.22%
EPS Next 5Y44.65%
Revenue Next Year9.25%
Revenue Next 2Y10.15%
Revenue Next 3Y11.29%
Revenue Next 5Y10.99%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ACAD is valuated quite expensively with a Price/Earnings ratio of 42.82.
93.06% of the companies in the same industry are more expensive than ACAD, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of ACAD to the average of the S&P500 Index (27.41), we can say ACAD is valued expensively.
A Price/Forward Earnings ratio of 24.71 indicates a rather expensive valuation of ACAD.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ACAD indicates a rather cheap valuation: ACAD is cheaper than 91.46% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.19, ACAD is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.82 | ||
| Fwd PE | 24.71 |
4.2 Price Multiples
92.53% of the companies in the same industry are more expensive than ACAD, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, ACAD is valued cheaply inside the industry as 91.99% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 70.96 | ||
| EV/EBITDA | 35.62 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ACAD does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of ACAD may justify a higher PE ratio.
A more expensive valuation may be justified as ACAD's earnings are expected to grow with 49.22% in the coming years.
PEG (NY)3.74
PEG (5Y)N/A
EPS Next 2Y33.01%
EPS Next 3Y49.22%
5. Dividend
5.1 Amount
ACAD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
20.98
-1.08 (-4.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners104.58%
Inst Owner Change0%
Ins Owners0.31%
Ins Owner Change3.85%
Market Cap3.51B
Analysts76.15
Price Target27.54 (31.27%)
Short Float %9.31%
Short Ratio6.83
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-56.13%
Min EPS beat(2)-109.07%
Max EPS beat(2)-3.19%
EPS beat(4)2
Avg EPS beat(4)-15.12%
Min EPS beat(4)-109.07%
Max EPS beat(4)41.97%
EPS beat(8)5
Avg EPS beat(8)19.9%
EPS beat(12)7
Avg EPS beat(12)13.32%
EPS beat(16)10
Avg EPS beat(16)17.13%
Revenue beat(2)1
Avg Revenue beat(2)-4.13%
Min Revenue beat(2)-8.33%
Max Revenue beat(2)0.08%
Revenue beat(4)2
Avg Revenue beat(4)-2.23%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.66%
Revenue beat(8)5
Avg Revenue beat(8)0.17%
Revenue beat(12)6
Avg Revenue beat(12)-0.72%
Revenue beat(16)7
Avg Revenue beat(16)-1.86%
PT rev (1m)1.04%
PT rev (3m)8.69%
EPS NQ rev (1m)-2.3%
EPS NQ rev (3m)-18.19%
EPS NY rev (1m)-9.94%
EPS NY rev (3m)-19.09%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)-0.43%
Revenue NY rev (1m)-0.09%
Revenue NY rev (3m)0.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.82 | ||
| Fwd PE | 24.71 | ||
| P/S | 3.53 | ||
| P/FCF | 70.96 | ||
| P/OCF | 23.57 | ||
| P/B | 4.59 | ||
| P/tB | 5.42 | ||
| EV/EBITDA | 35.62 |
EPS(TTM)0.49
EY2.34%
EPS(NY)0.85
Fwd EY4.05%
FCF(TTM)0.3
FCFY1.41%
OCF(TTM)0.89
OCFY4.24%
SpS5.95
BVpS4.57
TBVpS3.87
PEG (NY)3.74
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.23% | ||
| ROE | 29.93% | ||
| ROCE | 10.62% | ||
| ROIC | 9.3% | ||
| ROICexc | 9.3% | ||
| ROICexgc | 10.83% | ||
| OM | 8.84% | ||
| PM (TTM) | 22.99% | ||
| GM | 92.08% | ||
| FCFM | 4.97% |
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
F-Score5
Asset Turnover0.88
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 151.14% | ||
| Profit Quality | 21.61% | ||
| Current Ratio | 2.87 | ||
| Quick Ratio | 2.8 | ||
| Altman-Z | 4.78 |
F-Score5
WACC9.68%
ROIC/WACC0.96
Cap/Depr(3y)241.2%
Cap/Depr(5y)203.04%
Cap/Sales(3y)1.85%
Cap/Sales(5y)1.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5000%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
EPS Next Y11.46%
EPS Next 2Y33.01%
EPS Next 3Y49.22%
EPS Next 5Y44.65%
Revenue 1Y (TTM)22.39%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%18.7%
Revenue Next Year9.25%
Revenue Next 2Y10.15%
Revenue Next 3Y11.29%
Revenue Next 5Y10.99%
EBIT growth 1Y1912.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.12%
EBIT Next 3Y44.84%
EBIT Next 5Y49.94%
FCF growth 1Y188.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y367.79%
OCF growth 3YN/A
OCF growth 5YN/A